

| Package | Price per Dose | Price | |
|---|---|---|---|
| 360 pills | £0.64 | £327.79 £229.45 Free shipping | |
| 180 pills | £0.69 | £178.49 £124.94 | |
| 120 pills | £0.74 | £126.56 £88.59 | |
| 90 pills | £0.81 | £103.84 £72.69 | |
| 60 pills | £0.87 | £74.63 £52.24 | |
| 30 pills | £1.02 | £43.80 £30.66 | |
| 360 pills | £0.64 | £327.79 £229.45 Free shipping | |
| 180 pills | £0.69 | £178.49 £124.94 | |
| 120 pills | £0.74 | £126.56 £88.59 | |
| 90 pills | £0.81 | £103.84 £72.69 | |
| 60 pills | £0.99 | £84.37 £59.06 | |
| 30 pills | £1.06 | £45.42 £31.80 | |
| 360 pills | £1.01 | £519.28 £363.50 Free shipping | |
| 180 pills | £1.05 | £269.37 £188.56 Free shipping | |
| 120 pills | £1.12 | £193.10 £135.17 | |
| 90 pills | £1.22 | £155.77 £109.04 | |
| 60 pills | £1.31 | £111.96 £78.37 | |
| 30 pills | £1.40 | £60.03 £42.02 |
Carbamazepine is a medicine classified as an anticonvulsant (a drug that helps prevent seizures) that has been used for many years in clinical practice. It is also prescribed for certain nerve pain conditions, such as trigeminal neuralgia, where sudden, sharp facial pain can occur.
In clinical use, carbamazepine stabilises electrical activity in nerve cells to reduce abnormal impulses. This mechanism helps prevent seizures and can lessen episodes of neuropathic pain for some people. The effect on nerve cells is achieved through interactions with cellular proteins in the nerve cell membrane that respond to electrical signals.
The medicine is commonly prescribed as Tegretol (brand name) or carbamazepine (generic name). It may be prescribed alone or as part of a broader treatment plan that includes other medicines and non-drug therapies. Adherence to the prescribed regimen is important for the best possible outcome.
Trigeminal neuralgia and certain seizure types may respond to carbamazepine when other treatments have not provided sufficient relief. It is important that the use of tegretol is reviewed regularly by a healthcare professional to balance benefits with potential risks and to adjust therapy if needed.
Depending on local rules, a prescription may be required to obtain tegretol. The information provided here supports informed discussion with a clinician or pharmacist about suitability, safety monitoring, and practical use.
Tegretol contains the active ingredient carbamazepine, which acts on nerve cells in the brain and peripheral nerves. It is used to control seizures of various types and to relieve certain nerve pains.
Carbamazepine reduces the tendency of nerve membranes to become overexcited by blocking voltage-gated sodium channels. This stabilises electrical activity and helps prevent the spread of abnormal impulses that can trigger seizures or pain episodes.
Because carbamazepine influences liver enzymes, its effects can also alter the levels of other medicines in the body. Coordinated management with a healthcare professional ensures any potential interactions are considered and monitored.
When used for epilepsy, tegretol is typically started at a low dose and gradually increased to achieve an effective balance between control of seizures and tolerability. The speed of dose adjustment and target level are tailored to the individual’s response and tolerability.
For trigeminal neuralgia or other neuropathic pain conditions, the aim is to reduce the frequency or severity of pain attacks while minimising adverse effects. Regular review remains essential to confirm continued benefit and safety.
Tegretol should not be used by individuals with a history of hypersensitivity to carbamazepine or to any ingredients in the product. Severe allergic reactions may occur in rare cases and require urgent medical attention.
Porphyria, a group of rare metabolic disorders, is a recognised contraindication for tegretol in many guidelines. If porphyria has occurred in the past, the risks and benefits of ongoing treatment must be discussed with a healthcare professional.
Severe bone marrow suppression or a history of significant blood dyscrasias (such as a dangerously low white blood cell count or platelet count) would require careful consideration before starting tegretol. Blood test results may influence whether treatment proceeds.
Severe hepatic impairment or active liver disease may increase the risk of adverse effects and requires specialist consideration before initiating therapy. Liver function tests may be used to guide dosing decisions during treatment.
Concurrent use with certain medicines known to interact strongly with tegretol is a consideration. A healthcare professional will review all medicines, including those obtained without prescription, to avoid dangerous interactions. The use of monoamine oxidase inhibitors (MAO inhibitors) is generally avoided with tegretol due to potential risks.
Allergic reactions to excipients or prior Stevens–Johnson syndrome (a rare, severe skin reaction) associated with carbamazepine would be a contraindication. If a history of such reactions exists, alternative therapies should be discussed with a clinician.
Regular monitoring is recommended because tegretol can affect the function of various organs and blood cells. Blood tests, kidney function tests, and liver function tests may be performed to check safety and to guide dosing decisions.
Hyponatraemia (low blood sodium) is a known potential side effect. Certain individuals, such as older adults or those taking other medicines affecting sodium balance, may be more at risk. Symptoms such as confusion, headache, or unusual fatigue should be reported promptly.
Rashes or skin changes may occur, especially in the early weeks of treatment. Any widespread rash, blistering, fever, or mucous membrane symptoms require immediate medical assessment and, in many cases, stopping tegretol is advised until evaluated by a clinician.
Drowsiness, dizziness, or impaired coordination can occur and may affect daily activities such as driving. If these effects persist, consult a clinician before continuing to operate machinery or drive vehicles.
Seizure control or pain relief may not be immediate. The response to tegretol can take days to weeks, and treatment plans may include gradual dose adjustments and coordination with other therapies. Do not adjust the dose without professional guidance.
General adverse effects are reported with tegretol and may vary in frequency and severity. The information below groups effects by body system, with practical guidance on what to do if they occur.
For any new symptoms or concerns, a healthcare professional should be consulted. If symptoms are severe or cause confusion, seek urgent medical help.
Medical advice should be sought if adverse effects persist, worsen, or interfere with daily life. The presence of multiple mild effects may still require review to determine whether continuation is appropriate.
Drowsiness, dizziness, vertigo, and unsteadiness may occur. These effects are usually most noticeable when treatment is started or after a dose increase.
Ataxia (unsteadiness when walking) or poor coordination may affect balance. Caution is advised when standing up quickly to prevent falls.
Rash, itchiness, or hives may develop. Severe rash with fever or skin blistering requires urgent medical evaluation and possible cessation of tegretol.
Allergic reactions may present as swelling, severe itchy rash, or breathing difficulties. Immediate medical attention is required in such cases.
Changes in blood cell counts may occur, increasing the risk of infection or bleeding. Blood tests may be used to monitor these parameters during treatment.
Fever, sore throat, or easy bruising should be reported promptly as they could indicate a problem requiring investigation or treatment adjustment.
Elevations in liver enzymes or signs of liver irritation may be detected on tests or present as abdominal pain or jaundice (yellowing of the skin or eyes).
Digestive symptoms such as nausea, vomiting, diarrhoea, or abdominal discomfort can occur and are typically monitored to decide whether dose adjustments are needed.
Low sodium levels may lead to confusion, headaches, or weakness. Symptoms should be reported promptly, especially in older adults or those taking other medications affecting sodium balance.
Weight changes and appetite fluctuations may be observed in some individuals during tegretol therapy.
Palpitations or changes in heart rhythm are possible but uncommon. Blood pressure changes may occur in some patients and require monitoring, particularly in those with pre-existing heart conditions.
Blurred vision, double vision, or інших visual disturbances may occur. If vision changes are persistent, medical evaluation is advised to determine causation and management.
Interactions with other medicines can affect tegretol levels, seizure control, or safety. A formal drug interaction check is recommended when starting or stopping any therapy.
Prescription medicines that are enzyme inducers or inhibitors can alter tegretol levels. Examples include certain antibiotics, antifungals, and other antiseizure medications. A clinician will review all prescriptions to minimise risk.
Over-the-counter medicines and herbal supplements may also interact. St John’s wort, for example, can lower tegretol levels, potentially reducing efficacy. Grapefruit juice may influence metabolism in some individuals. Confirm with a pharmacist before combining tegretol with non-prescription products.
Alcohol can enhance sedative effects and impact coordination. It is generally advised to limit or avoid alcohol while taking tegretol, depending on tolerability and clinician guidance.
Supplements and alternative therapies should be discussed with a healthcare professional before use. Adjustments to tegretol therapy may be required if interactions are identified.
Pregnancy: The use of tegretol during pregnancy is considered only when potential benefits justify the potential risks to the developing fetus. The decision should be made in collaboration with a healthcare professional, and folic acid supplementation may be advised to reduce certain risks. Breastfeeding is a consideration, as carbamazepine passes into breast milk and may affect the infant; discuss monitoring and alternatives with a clinician.
Older adults: Age-related sensitivity to side effects may be increased. Dose adjustments and careful monitoring are often required to balance safety with seizure or pain control.
Children: Tegretol is used for certain seizure types in childhood but requires careful dosing and monitoring for side effects. Growth, behaviour, and cognitive development may require periodic assessment during therapy.
Liver impairment: In individuals with liver disease, tegretol requires careful evaluation. Hepatic status may influence dosing decisions and safety monitoring guidelines.
Take tegretol exactly as prescribed. Do not alter the dose or frequency without consulting a healthcare professional.
Take the medication with meals if advised by the prescriber to reduce stomach upset. Swallow tablets whole unless directed otherwise by a clinician.
If a dose is missed, follow the guidance provided by the clinician or patient information leaflet. Do not double the next dose to compensate for a missed one unless explicitly advised.
Do not stop tegretol abruptly. A gradual reduction over time may be recommended to reduce the risk of seizure worsening or rebound symptoms. Seek medical guidance before stopping therapy.
Storage should be in a cool, dry place away from light and moisture. Keep tegretol out of reach of children. Do not use after the expiry date printed on the package.
Adverse effects or signs of possible organ injury should be discussed with a clinician promptly. Seek urgent medical help if signs suggestive of a serious reaction occur (for example persistent swelling, severe rash, or yellowing of the skin). A safety review may be required if unexpected symptoms appear.
General safety-focused information is provided in response to common concerns. The guidance is not a substitute for a personalised discussion with a healthcare professional.
Questions below are intended to address practical safety considerations, including when to seek medical help and how to manage interactions and monitoring during tegretol therapy.
Advice may vary depending on local guidelines and individual health status. Contact a pharmacist or doctor for tailored information if any doubt arises.
Driving or operating machinery may be affected if drowsiness, dizziness, or impaired coordination occurs. If these effects are present, driving should be avoided until they improve or a clinician provides guidance.
The decision to use tegretol in pregnancy should be based on a careful assessment of benefits and risks. Guidance from a clinician with experience in pregnancy-related considerations is advised, and folic acid supplementation may be recommended.
Fever or sore throat can be signs of infection or changes in blood counts. Medical evaluation is advised, and blood tests may be performed to assess safety during treatment.
Alcohol may intensify dizziness and sedation. Caution is advised, and the amount consumed should be discussed with a clinician. If intolerance develops, abstention may be recommended.
Regular monitoring is commonly recommended. Blood tests may check blood cell counts, liver function, and electrolyte balance. Abnormal results may lead to treatment adjustments.
Changes in seizure frequency or pain control may indicate a need for review. Any new or worsening symptoms should be discussed with a clinician to determine whether a dose change or additional therapy is required.
Yes. Some supplements can alter tegretol levels or safety. Always inform a healthcare professional about any herbal products being used before starting tegretol or when adding new supplements.
A sudden stop can worsen seizures or trigger rebound symptoms. If stopping is being considered, a gradual, planned reduction under medical supervision is typically advised.
Any significant skin rash or skin blistering should be reported urgently. Seek medical assessment promptly and follow the clinician’s instructions, which may include stopping tegretol.
Vision changes such as blurred or double vision, and dizziness, can occur. If these symptoms persist or worsen, medical advice should be sought to determine the cause and management plan.
Improvements may occur over days to weeks, depending on the condition being treated. Ongoing assessments are used to judge whether the treatment is achieving the expected benefit.
For any questions about safety, potential interactions, or testing plans, contact a pharmacist or a clinician. When in doubt, consult the official leaflet or seek professional advice before making changes to tegretol therapy.
14–21 days. Free from £151.46 .
5–9 days. £22.72
−10% when paying with cryptocurrency.
−10% on all repeat orders.
All orders are packed in neutral, unbranded boxes with no product name on the outside.
